Kristen Marks
Co-Director of the Cornell HIV/AIDS Clinical Trials Unit · Weill Cornell Medicine
Credentials: · · ·
History
PresentCornell HIV/AIDS Clinical Trials Unit · Weill Cornell Medicine
- Present
Research
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
New England Journal of Medicine · 2020 · 999 citations
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
New England Journal of Medicine · 2015 · 379 citations
Journal of Hepatology · 2007 · 209 citations
12 papers
10 papers
9 papers
8 papers
6 papers
6 papers
5 papers
- DB
5 papers
Grants
- 2016–2023
Accessible Care Intervention for Engaging People Who Inject Illicit Drugs (PWID) in Hepatitis C Care
National Institute on Drug Abuse · R01
PI · $2.8M · Graduate School of Public Health and Health Policy
- 2005–2010
Thrombocytopenia & HIV/HCV: Risk Factors & Treatment
National Institute of Allergy and Infectious Diseases · K23
Contact PI · $657.5K · Weill Medical Coll of Cornell Univ
- 2005–2007
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $52K · Weill Medical Coll of Cornell Univ
Clinical trials
- 2017–2021
Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)
Principal investigator · Completed
City University of New York, School of Public Health
- 2005–2010
Principal investigator · Terminated · Phase 4
National Institute of Allergy and Infectious Diseases (NIAID)